DigestRedComo funciona
Red
/
Empresas
No
No verificado

Novo Nordisk

Sobre qué escribimos

Crónica de sociedadFitnessMedicina - VariosSaludSociedad/Prensa del corazón

5 Comunicados de prensa

Ver todos los comunicados de prensa
Press Release cover image
11/07/2026
Salud
Fitness
Sociedad/Prensa del corazón
Crónica de sociedad
Medicina - Varios
Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
Fuente
Novo Nordisk
Editor
PR News Wire
1.00
0
Press Release cover image
26/06/2026
Salud
Fitness
Sociedad/Prensa del corazón
Crónica de sociedad
Medicina - Varios
Medio Ambiente/Ecología
Agricultura
Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
Fuente
Novo Nordisk
Editor
PR News Wire
1.00
0
Press Release cover image
06/06/2026
Sociedad/Prensa del corazón
Crónica de sociedad
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
Fuente
Novo Nordisk
Editor
PR News Wire
1.00
0
Press Release cover image
29/04/2026
Salud
Fitness
Medicina - Varios
Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM
Fuente
Novo Nordisk
Editor
PR News Wire
1.00
0
Press Release cover image
01/04/2026
Salud
Fitness
Medicina - Varios
Wegovy®▼(semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥27 kg/m2)[1]
Fuente
Novo Nordisk
Editor
PR News Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0